HP
NAMS icon

HealthInvest Partners’s NewAmsterdam Pharma NAMS Stock Holding History

HealthInvest Partners’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.43M Buy
248,848
+154,052
+163% +$5.08M 2.27% 21
2026
Q1 		$5.51M Sell
94,796
-102,240
-52% -$3.33M 1.78% 26
2025
Q4 		$6.91M Buy
197,036
+3,411
+2% +$124K 2.21% 20
2025
Q3 		$585K Buy
193,625
+36,402
+23% +$873K 2.17% 17
2025
Q2 		$2.85M Buy
157,223
+49,440
+46% +$902K 1.22% 26
2025
Q1 		$2.21M Sell
107,783
-31,200
-22% -$694K 0.97% 26
2024
Q4 		$3.56M Hold
138,983
– – 1.69% 19
2024
Q3 		$2.31M Buy
138,983
+63,189
+83% +$1.09M 1.08% 25
2024
Q2 		$1.46M Buy
75,794
+53,400
+238% +$1.07M 0.89% 27
2024
Q1 		$530K Buy
+22,394
New +$455K 0.32% 42

Other funds holding NAMS

PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
MMC
Mizuho Markets Cayman Grand Cayman, Cayman Islands $2.67B AUM 103.47% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
EC
Eleva Capital Paris, France $343M AUM
SOAM
SBI Okasan Asset Management Tokyo, Japan $3.04B AUM
AA
AlphaCentric Advisors San Juan, Puerto Rico $118M AUM

HealthInvest Partners's NAMS Position: Q2 2026 in Review

HealthInvest Partners increased its NewAmsterdam Pharma (NAMS) stake by 163% in Q2 2026, buying an estimated $5.08M and bringing the position to 248,848 shares worth $8.43M. The position accounts for 2.27% of the portfolio, ranked #21.

HealthInvest Partners first reported a position in NAMS in Q1 2024 and has held it in 10 quarters since. 25 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • HealthInvest Partners held 248,848 shares of NewAmsterdam Pharma worth $8.43M as of Q2 2026.
  • HealthInvest Partners bought 154,052 NewAmsterdam Pharma shares in Q2 2026, an estimated $5.08M.
  • NewAmsterdam Pharma made up 2.27% of HealthInvest Partners's portfolio in Q2 2026, its #21 holding.
  • HealthInvest Partners first reported a position in NewAmsterdam Pharma in Q1 2024 and has held it in 10 quarters since.
  • 25 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on HealthInvest Partners's 13F filing for Q2 2026, filed 24 Jul 2026.